我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

G-CSF在心血管疾病方面的临床研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第1期
页码:
83-86
栏目:
综述
出版日期:
2013-12-02

文章信息/Info

Title:
Clinical research of granulocyte colony-stimulating factor in cardiovascular disease
作者:
王雪婷; 罗 明
(同济大学附属同济医院心内科，上海 200065)
Author(s):
WANG Xue-ting;  LUO Ming
(Department of Cardiology, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China)
关键词:
粒细胞集落刺激因子; 心血管疾病; 骨髓干细胞
Keywords:
G-CSF;  cardiovascular diseases;  bone marrow stem cells
分类号:
R54
DOI:
-
文献标识码:
A
摘要:
粒细胞集落刺激因子（G-CSF）对心脏有直接保护作用，也可以通过刺激骨髓干细胞动员至外周血，间接发挥作用，加速损伤修复，减少心血管不良事件。近年来涌现出大量关于G-CSF在心血管疾病方面的临床研究文章，G-CSF使用的剂量、时机、疗程、联用药物等均会影响治疗效果，本文总结了国内外的研究结果，可为G-CSF在心血管疾病方面进一步的临床应用提供依据。
Abstract:
In addition to directly protecting the heart, granulocyte colony-stimulating factor (G-CSF) also exerts some indirect protective effects on accelerating repair and reducing adverse cardiovascular events by stimulating the bone marrow to mobilize the stem cell to the peripheral blood. In recent years a large number of clinical studies have been performed to detect the effect of G-CSF on cardiovascular diseases. The dosage of G-CSF, time of use, duration of treatment and combined therapy with other drugs may all influence the outcomes. In this article we summarize the clinic research results at home and abroad to provide more information for the further study of G-CSF and cardiovascular diseases.

参考文献/References

[1]Sanganalmath SK,Abdel-Latif A,Bolli R,et al.Hematopoietic cytokines for cardiac repair:mobilization of bone marrow cells and beyond[J].Basic Res Cardiol,2011,106(5):709-733.
[2]Ma H,Gong H,Chen Z,et al.Association of Stat3 with HSF1 plays a critical role in G-CSF-induced cardio-protection against ischemia/reperfusion injury[J].J Mol Cell Cardiol,2012,52(6):1282-1290.
[3]Uchiyama R,Hasegawa H,Kameda Y,et al.Role of regulatory T cells in atheroprotective effects of granulocyte colony-stimulating factor[J].J Mol Cell Cardiol,2012,52(5):1038-1047.
[4]Szardien S,Nef HM,Voss S,et al.Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1β synthesis[J].Eur Heart J,2012,33(5):595-605.
[5]Milberg P,Klocke R,Frommeyer G,et al.G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis,angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure[J].Basic Res Cardiol,2011,106(6):995-1008.
[6]Baldo MP,Davel AP,Damas-Souza DM,et al.The antiapoptotic effect of granulocyte colony-stimulating factor reduces infarct size and prevents heart failure development in rats[J].Cell Physiol Biochem,2011,28(1):33-40.
[7]Li JM,Yao ZF,Zou YZ,et al.The therapeutic potential of G-CSF in pressure overload induced ventricular reconstruction and heart failure in mice[J].Mol Biol Rep,2012,39(1):5-12.
[8]Pasquet S,Sovalat H,Hénon P,et al.Long-term benefit of intracardiac delivery of autologous granulocyte-colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct[J].Cytotherapy,2009,11(8):1002-1015.
[9]Guo SZ,Wang NF,Zhou L,et al.Influence of granulocyte colony-stimulating factor on cardiac function in patients with acute myocardial infarction and leukopenia after revascularization[J].Chin Med J(Engl),2010,123(14):1827-1832.
[10]Achilli F,Malafronte C,Lenatti L,et al.Granulocyte colony-stimulating factor attenuates left ventricular remodeling after acute anterior STEMI:results of the single-blind,randomized,placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI)Trial[J].Eur J Heart Fail,2010,12(10):1111-1121.
[11]Karimabad HM,Shabestari M,Baharvand H,et al.Lack of beneficial effects of granulocyte colony-stimulating factor in patients with subacute myocardial infarction undergoing late revascularization: a double-blind, randomized, placebo-controlled clinical trial[J].Acta Cardiol,2011,66(2):219-224.
[12]Maggiolini S,Lenatti L,Malafronte C,et al.G-CSF administration in acute myocardial infarction:what is the best timing?[J].Cardiovasc Res,2011,91(1):180-182.
[13]Zimmet H,Porapakkham P,Porapakkham P,et al.Short-and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction:a meta-analysis of randomized control trials[J].Eur J Heart Fail,2012,14(1):91-105.
[14]Stein A,Zohlnhfer D,Pogatsa-Murray G,et al.Expression of CXCR4,VLA-1,LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction[J].Thromb Haemost,2010,103(3):638-643.
[15]Theiss HD,Brenner C,Engelmann MG,et al.Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis[J].Int J Cardiol,2010,145(2):282-284.
[16]Gu X,Xie Y,Gu J,et al.Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure--a pilot study[J].Circ J,2011,75(4):955-963.
[17]Arnous S,Mozid A,Mathur A.The Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial:study design[J].Regen Med,2011,6(4):525-533.
[18]Santoso T,Irawan C,Alwi I,et al.Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction:one-year follow-up of a phase 1 study[J].Acta Med Indones,2011,43(2):112-121.
[19]Dato GM,Sansone F,Omedé P,et al.Preoperative mobilization of bone marrow-derived cells followed by revascularization surgery:early and long-term outcome[J].Int J Artif Organs,2012,35(1):67-76.
[20]Hohensinner PJ,Rychli K,Zorn G,et al.Macrophage-modulating cytokines predict adverse outcome in heart failure[J].Thromb Haemost,2010,103(2):435-441.
[21]Leone AM,Giannico MB,Bruno I,et al.Safety and efficacy of G-CSF in patients with ischemic heart failure:the CORNER(Cell Option For Recovery in the Non-Eligible Patients for Revascularization)study[J].Int J Cardiol,2011,150(1):75-78.
[22]Konenkov VI,Pokushalov EA,Poveshchenko OV,et al.Phenotype of peripheral blood cells mobilized by granulocyte colony-stimulating factor in patients with chronic heart failure[J].Bull Exp Biol Med,2012,153(1):124-128.
[23]Toyama T,Hoshizaki H,Kasama S,et al.Low-dose and long-term G-CSF treatment can improve severe myocardial ischemia in patients with severe coronary artery disease[J].J Nucl Cardiol,2011,18(3):463,471.
[24]Povsic TJ,Losordo DW,Story K,et al.Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI[J].Am Heart J,2012,164(5):689-697.
[25]Chih S,Macdonald PS,McCrohon JA,et al.Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation:a placebo controlled crossover trial[J].Heart,2012,98(4):282-290.
[26]Wyderka R,Wojakowski W,Jadczyk T,et al.Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction[J].Mediators Inflamm,2012,2012:564027.
[27]Shim W,Mehta A,Lim SY,et al.G-CSF for stem cell therapy in acute myocardial infarction: friend or foe?[J].Cardiovasc Res,2011,89(1):20-30.
[28]van der Pol A,Domian I,van der Meer P.Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?[J].Eur J Heart Fail,2012,14(1):1-4.

备注/Memo

备注/Memo:
收稿日期：2013-05-18.通讯作者：罗明，主任医师，主要从事高血压基础与临床心力 衰竭研究 Email：lmfc84@yahoo.com.cn 作者简介：王雪婷，硕士生 Email：1213889193@qq.com
更新日期/Last Update: 2014-01-20